STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

Good morning. The Pharmalot team is feeling buoyant today, despite the overcast skies outside. To set the tone, we've selected a delightful butter pecan flavor for our beverage selection. Today's featured stories focus on Western pharmaceutical companies advocating for the right to continue their partnerships with Chinese partners, despite a 2025 law restricting U.S. investments in Chinese technology.

An industry trade group has been lobbying the Treasury Department to ensure that the regulations being drafted for the law do not hinder their ability to engage in cross-border collaborations. The Comprehensive Outbound Investment National Security Act, or COINS, mandates the federal government to scrutinize transactions involving sensitive technology with specific nations.

As of now, the Treasury Department appears hesitant to extend the restrictions to pharmaceuticals. Meanwhile, the FDA is poised to review a Grail blood test that holds the potential to detect multiple types of cancer in their early stages, thereby increasing the possibilities of effective treatment. Although the test is currently available for laboratory-based diagnosis, FDA approval would likely pave the way for Medicare and other insurance payers to cover the cost.

Despite the overall positive sentiment among investors, the FDA documents reveal a potential catch that could complicate the outlook for the company. Delve deeper into STAT+ for a comprehensive examination of these developments.